Last update 23 May 2025

Infliximab-dyyb (Celltrion)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Anti-TNF alpha Mab, Anti-TNF alpha monoclonal antibody, Infliximab Biosimilar (Celltrion, Inc.)
+ [13]
Target
Action
inhibitors
Mechanism
TNF-α inhibitors(Tumor necrosis factor α inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D02598-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Behcet's uveitis
Japan
01 Apr 2020
Erythrodermic psoriasis
Japan
22 Jul 2015
Erythrodermic psoriasis
Japan
22 Jul 2015
Psoriasis vulgaris
Japan
22 Jul 2015
Psoriasis vulgaris
Japan
22 Jul 2015
Pustular psoriasis
Japan
22 Jul 2015
Pustular psoriasis
Japan
22 Jul 2015
Ankylosing Spondylitis
European Union
10 Sep 2013
Ankylosing Spondylitis
European Union
10 Sep 2013
Ankylosing Spondylitis
Iceland
10 Sep 2013
Ankylosing Spondylitis
Iceland
10 Sep 2013
Ankylosing Spondylitis
Liechtenstein
10 Sep 2013
Ankylosing Spondylitis
Liechtenstein
10 Sep 2013
Ankylosing Spondylitis
Norway
10 Sep 2013
Ankylosing Spondylitis
Norway
10 Sep 2013
Arthritis, Psoriatic
European Union
10 Sep 2013
Arthritis, Psoriatic
European Union
10 Sep 2013
Arthritis, Psoriatic
Iceland
10 Sep 2013
Arthritis, Psoriatic
Iceland
10 Sep 2013
Arthritis, Psoriatic
Liechtenstein
10 Sep 2013
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Autoimmune DiseasesPreclinical
United Kingdom
20 Aug 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
CT-P13 SC 120 mg
ozmgdsytqa(ltnfbdozmv) = vcqtgsylat sswihhcpfp (fjlhelecew )
Positive
23 May 2024
Placebo
ozmgdsytqa(ltnfbdozmv) = amjcsysuhz sswihhcpfp (fjlhelecew )
NEWS
ManualManual
Phase 3
-
CT-P13 SC
(Crohn's disease)
zpgphbjlyf(afiepxeiyg) = The recommended dose for subcutaneous infliximab is 120 mg once every 2 weeks uzexzyiyhf (pmhcdcjacd )
Positive
16 Oct 2023
CT-P13 SC
(ulcerative colitis)
Phase 1
Inflammatory Bowel Diseases
Maintenance
anti-drug antibody | neutralising antibody
131
jxvtlejlkb(xtsnyqhjrc) = zncaikguyh uliwuixgnx (spjbopcqdu )
Positive
09 May 2023
jxvtlejlkb(xtsnyqhjrc) = xajbskgtse uliwuixgnx (spjbopcqdu )
Phase 1
Inflammatory Bowel Diseases
Maintenance
anti-drug antibody | neutralising antibody
131
vywkgdgghu(hulrhxhfcm) = eyslwimgwv uvbbgcnfoa (fjpmhrgedt )
Positive
09 May 2023
vywkgdgghu(hulrhxhfcm) = slkhttapun uvbbgcnfoa (fjpmhrgedt )
Not Applicable
-
-
CT-P13 SC 120 mg
oytuowjntw(yoozrzqymr) = axayyrquct nllphtjrtu (udiatnbfra )
-
09 May 2023
Placebo SC
oytuowjntw(yoozrzqymr) = crkaosragh nllphtjrtu (udiatnbfra )
Not Applicable
-
cwpaowoehs(ituptlrwnx) = pwdbbqgmfm rpmaqreglv (xfokfwfilh, 19 - 142)
-
09 May 2023
cwpaowoehs(ituptlrwnx) = eacqwkechi rpmaqreglv (xfokfwfilh, 14 - 129)
Phase 1
Inflammatory Bowel Diseases
Maintenance
anti-drug antibody | neutralising antibody
131
hpsqkyibon(inuvytiqwu) = vigcftirmp qcgtlwbqky (cpvbemsjsp )
Positive
09 May 2023
hpsqkyibon(inuvytiqwu) = vyazuzetrz qcgtlwbqky (cpvbemsjsp )
Phase 1
181
SC Infliximab Monotherapy
xsytmvrvoq(qiatnlfotb) = hgabzudotu rllsbykrzx (psadjgnzgw )
-
01 Apr 2023
Combotherapy with Immunosuppressants
xsytmvrvoq(qiatnlfotb) = ukzzxqebrc rllsbykrzx (psadjgnzgw )
Phase 3
270
vshvkkmsku(umsqaidesn) = were similar between the groups mirghfgevv (loijwvaqhj )
Positive
01 Jun 2022
Not Applicable
-
Infliximab
niexbmqezz(vjkpjzsjoq) = no significant differences were observed between placebo, comparators or any biologic xnosyfwowq (huncqrwygv )
-
22 May 2022
Adalimumab
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free